Lumos Diagnostics Holdings Ltd
ASX:LDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
D-Wave Quantum Inc
NYSE:QBTS
|
CA |
|
T
|
Tirupati Forge Ltd
NSE:TIRUPATIFL
|
IN |
Lumos Diagnostics Holdings Ltd
Revenue
Lumos Diagnostics Holdings Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
Revenue
$12.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Nanosonics Ltd
ASX:NAN
|
Revenue
AU$207.3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
24%
|
|
|
Polynovo Ltd
ASX:PNV
|
Revenue
AU$138.1m
|
CAGR 3-Years
38%
|
CAGR 5-Years
41%
|
CAGR 10-Years
77%
|
|
|
SDI Ltd
ASX:SDI
|
Revenue
AU$111.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
|
Anteris Technologies Ltd
ASX:AVR
|
Revenue
AU$1.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Ansell Ltd
ASX:ANN
|
Revenue
$2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Lumos Diagnostics Holdings Ltd
Glance View
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.
See Also
What is Lumos Diagnostics Holdings Ltd's Revenue?
Revenue
12.4m
USD
Based on the financial report for Jun 30, 2025, Lumos Diagnostics Holdings Ltd's Revenue amounts to 12.4m USD.
What is Lumos Diagnostics Holdings Ltd's Revenue growth rate?
Revenue CAGR 5Y
17%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Lumos Diagnostics Holdings Ltd have been 2% over the past three years , 17% over the past five years .
